生长激素治疗对特发性矮小症患儿血清胰岛素样生长因子1和成纤维生长因子21水平的影响  

Effect of growth hormone therapy on serum insulin-like growth factor 1 and fibroblast growth factor 21 levels in children with idiopathic nanosomia

作　　者：上官丹 SHANGGUAN Dan(Department of Pediatrics,Fuzhou First People's Hospital,Fuzhou,Jiangxi,344000,China)

机构地区：[1]抚州市第一人民医院儿科,江西抚州344000

出　　处：《当代医学》2024年第10期40-43,共4页Contemporary Medicine

基　　金：抚州市指导性科技计划项目(抚科计字〔2021〕21号26号)。

摘　　要：目的研究生长激素治疗对特发性矮小症患儿血清胰岛素样生长因子1(IGF1)和成纤维生长因子21(FGF21)水平的影响。方法选取2021年1月至2022年1月抚州市第一人民医院收治的60例特发性矮小症患儿作为研究对象,根据治疗方案不同分为对照组与观察组,每组30例。对照组给予葡萄糖酸钙口服液治疗,观察组在对照组的基础上采用生长激素治疗。比较两组治疗前后骨龄、预测成年身高、血清25-羟维生素D[25(OH)D]、IGF1及FGF21水平。结果治疗4、8、12个月后,观察组骨龄、成年预测身高、血清25-(OH)D水平、IGF1水平、FGF21水平均高于治疗前,对照组治疗12个月后骨龄、成年预测身高、血清25-(OH)D水平、IGF1水平、FGF21水平均高于治疗前,差异有统计学意义(P<0.05)。治疗4、8、12个月后,观察组骨龄、成年预测身高、血清25-(OH)D水平、IGF1水平、FGF21水平均高于对照组,差异有统计学意义(P<0.05)。结论生长激素治疗对特发性矮小症患儿的血清IGF1和FGF21水平影响显著,能更有效地调节血清25-(OH)D、IGF1和FGF21水平,提高骨龄、成年预测身高,促进特发性矮小症患儿的生长发育,起到更佳的治疗效果。Objective To investigate the effects of growth hormone therapy on serum insulin-like growth factor 1(IGF1)and fibroblast growth factor 21(FGF21)levels in children with idiopathic nanosomia.Methods 60 children with idiopathic nanosomia treated in Fuzhou First People's Hospital from January 2021 to January 2022 were selected as the research subjects,and they were divided into the control group and the observation group according to different treatment plans,with 30 cases in each group.The control group was treated with calcium gluconate oral solution,the observation group was treated with growth hormone on the basis of the control group,the bone age,predicted adult height,serum 25-hydroxyvitamin D(25-[OH]D),IGF1 and FGF21 levels were compared between the two groups before and after treatment.Results After 4,8 and 12 months of treatment,the bone age,adult predicted height,serum 25-(OH)D level,IGF1 level and FGF21 level in the observation group were higher than those before treatment,while bone age,adult predicted height,serum 25-(OH)D level,IGF1 level and FGF21 level after 12 months in the control group were higher than before treatment,the differences were statistically significant(P<0.05).After 4,8 and 12 months of treatment,bone age,adult predicted height,serum 25-(OH)D level,IGF1 level and FGF21 level in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.05).Conclusion Growth hormone therapy has significant effect on IGF1 and FGF21 in children with idiopathic short stature,can more effectively regulate serum 25-(OH)D,IGF1 and FGF21 levels,improve bone age and adult height height,and promote growth and development in children with idiopathic short stature,leading to better treatment outcomes.

关 键 词：生长激素 特发性矮小症 血清胰岛素样生长因子1 血清成纤维生长因子21 

分 类 号：R725.8[医药卫生—儿科]